{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:26:53Z","timestamp":1789586813929,"version":"build-2803163510"},"reference-count":76,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis B virus (HBV) infection remains a global health challenge, affecting over 254 million individuals chronically and contributing significantly to cirrhosis, liver failure, and hepatocellular carcinoma. Despite advancements in antiviral therapy, HBV reactivation remains a critical concern, particularly in immunosuppressed individuals, including non-transplant patients undergoing immunosuppressive therapy and solid organ transplant recipients. This review provides screening and management strategies for HBV reactivation in these populations.<\/jats:p>","DOI":"10.3390\/v17030388","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:46:41Z","timestamp":1741596401000},"page":"388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["HBV Reactivation in Immunosuppressed Patients: Screening, Prevention, and Management Including Solid Organ Transplant Recipients"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-6077","authenticated-orcid":false,"given":"Philip","family":"Vutien","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Washington Medical Center, 1959 NE Pacific Street, Box 356175, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA 94305, USA"},{"name":"Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, December 20). Hepatitis B: Key Facts and Epidemiology. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","article-title":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yeo","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis","volume":"57","author":"Dong","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Bowden","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Shih, C.A., Chen, W.C., Yu, H.C., Cheng, J.S., Lai, K.H., Hsu, J.T., Chen, H.C., and Hsu, P.I. (2015). Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132426"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","article-title":"Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations\u2014United States, 2023","volume":"72","author":"Conners","year":"2023","journal-title":"MMWR Recomm. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10620-017-4850-1","article-title":"Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network","volume":"63","author":"Kwak","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40780-024-00339-9","article-title":"A cross-sectional survey of hepatitis B virus screening in patients who received immunosuppressive therapy for rheumatoid arthritis in Japan","volume":"10","author":"Yanagisawa","year":"2024","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e29144","DOI":"10.1002\/jmv.29144","article-title":"Ultrasensitive PCR system for HBV DNA detection: Risk stratification for occult hepatitis B virus infection in English blood donors","volume":"95","author":"Fu","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Lu, W., Zeng, D., Huang, D., Lin, W., Yan, L., and Feng, Y. (2021). Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235617"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Inoue, T., and Tanaka, Y. (2019). The Role of Hepatitis B Core-Related Antigen. Genes, 10.","DOI":"10.3390\/genes10050357"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cerva, C., Salpini, R., Alkhatib, M., Malagnino, V., Piermatteo, L., Battisti, A., Bertoli, A., Gersch, J., Holzmayer, V., and Kuhns, M. (2022). Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020443"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lou, B., Ma, G., Lv, F., Yuan, Q., Xu, F., Dong, Y., Lin, S., Tan, Y., Zhang, J., and Chen, Y. (2021). Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.710528"},{"key":"ref_23","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: A systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.17155","article-title":"Meta-analysis: Hepatitis B reactivation in patients receiving biological therapy","volume":"56","author":"Eslick","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00535-016-1187-z","article-title":"Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy","volume":"51","author":"Hayashi","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(-)\/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e01393","DOI":"10.1016\/j.idcr.2022.e01393","article-title":"Late Hepatitis B reactivation after treatment with rituximab","volume":"27","author":"Pereira","year":"2022","journal-title":"IDCases"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/flgastro-2021-102064","article-title":"EASL clinical practice guidelines: Non-invasive liver tests for evaluation of liver disease severity and prognosis","volume":"13","author":"Archer","year":"2022","journal-title":"Frontline Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2020.02.009","article-title":"Hepatitis B Virus Reactivation Potentiated by Biologics","volume":"34","author":"Ogawa","year":"2020","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e3572","DOI":"10.1093\/cid\/ciaa1391","article-title":"Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","first-page":"14","article-title":"Chronic hepatitis B and HIV coinfection","volume":"31","author":"Corcorran","year":"2023","journal-title":"Top. Antivir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.cgh.2021.11.032","article-title":"Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV\/HBV Dual Infection: A Randomized Trial","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clml.2018.11.008","article-title":"Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial","volume":"19","author":"Liu","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Buti, M., Manzano, M.L., Morillas, R.M., Garcia-Retortillo, M., Martin, L., Prieto, M., Gutierrez, M.L., Suarez, E., Gomez Rubio, M., and Lopez, J. (2017). Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184550"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wu, Y., Huang, H., and Luo, Y. (2020). Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.610500"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gentile, G., and Antonelli, G. (2019). HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses, 11.","DOI":"10.3390\/v11111049"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840130402","article-title":"Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease","volume":"13","author":"Todo","year":"1991","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.1840130122","article-title":"Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis","volume":"13","author":"Davies","year":"1991","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: A systematic review","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1002\/lt.21900","article-title":"Outcomes after liver transplantation: Chronic kidney disease","volume":"15","author":"Bahirwani","year":"2009","journal-title":"Liver Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e938731","DOI":"10.12659\/AOT.938731","article-title":"Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation","volume":"28","author":"Cheng","year":"2023","journal-title":"Ann. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cgh.2022.01.035","article-title":"Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients","volume":"21","author":"Liu","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-017-0754-9","article-title":"Tenofovir Alafenamide: A Review in Chronic Hepatitis B","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.14218\/JCTH.2015.00041","article-title":"Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation","volume":"4","author":"Maiwall","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/apt.16374","article-title":"2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): Management of hepatitis B virus-related infection before and after liver transplantation","volume":"54","author":"Duvoux","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, P., Tam, N., Wang, H., Zheng, H., Chen, P., Wu, L., and He, X. (2014). Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104480"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/lt.20701","article-title":"Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis","volume":"12","author":"Zheng","year":"2006","journal-title":"Liver Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabine\/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management","volume":"15","author":"Huprikar","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e13514","DOI":"10.1111\/ctr.13514","article-title":"Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice","volume":"33","author":"Te","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yin, S., Zhang, F., Wu, J., Lin, T., and Wang, X. (2023). Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis. PLoS Med., 20.","DOI":"10.1371\/journal.pmed.1004196"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e15389","DOI":"10.1111\/ctr.15389","article-title":"Hepatitis B Virus Reactivation in Non-Liver Solid Organ Transplantation: Incidence and Risk Analysis","volume":"38","author":"Chiu","year":"2024","journal-title":"Clin. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2019.03.003","article-title":"Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis","volume":"70","author":"Wong","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","article-title":"Liver grafts from anti-hepatitis B core positive donors: A systematic review","volume":"52","author":"Cholongitas","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1111\/j.1399-0012.2011.01409.x","article-title":"Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts\u2014A systematic analysis","volume":"25","author":"Skagen","year":"2011","journal-title":"Clin. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100840","DOI":"10.1016\/j.trre.2024.100840","article-title":"Was antiviral prophylaxis necessary after kidney transplantation utilizing HBcAb+ donors? A systematic review and meta-analysis","volume":"38","author":"Yin","year":"2024","journal-title":"Transplant. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jss.2022.10.078","article-title":"Hepatitis B in Heart Transplant Donors and Recipients: A Systematic Review and Meta-Analysis","volume":"283","author":"Yost","year":"2023","journal-title":"J. Surg. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/TP.0b013e3181b4e1fd","article-title":"Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: An analysis of the United Network For Organ Sharing Database","volume":"88","author":"Dhillon","year":"2009","journal-title":"Transplantation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/tid.12280","article-title":"Hepatitis B core antibody-positive donors in cardiac transplantation: A single-center experience","volume":"16","author":"Horan","year":"2014","journal-title":"Transplant. Infect. Dis."},{"key":"ref_65","first-page":"80","article-title":"Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021","volume":"29","author":"Ali","year":"2023","journal-title":"Liver Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/jgh.15821","article-title":"Utilization of hepatitis B virus surface antigen positive grafts in liver transplantation: A matched study based on a national registry cohort","volume":"37","author":"Yu","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/SLA.0000000000005071","article-title":"Expanding the Donor Pool: First Use of Hepatitis B Virus Nat Positive Solid Organ Allografts Into Seronegative Recipients","volume":"274","author":"Delman","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jhep.2014.05.003","article-title":"Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation","volume":"61","author":"Yu","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2011.09.016","article-title":"Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool","volume":"56","author":"Loggi","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4254\/wjh.v13.i3.291","article-title":"Hepatitis D virus and liver transplantation: Indications and outcomes","volume":"13","author":"Muhammad","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","article-title":"Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine","volume":"147","author":"Lim","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cncr.29159","article-title":"Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population-based cohort study","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e14295","DOI":"10.1111\/tid.14295","article-title":"Utilization of Hepatitis B viremic donors (NAT+) leads to improved kidney transplant access for older adult recipients with little to no wait time","volume":"26","author":"Joyce","year":"2024","journal-title":"Transplant. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/liv.15703","article-title":"Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg-positive donors to HBsAg-negative recipients","volume":"43","author":"Yin","year":"2023","journal-title":"Liver Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/lt.22312","article-title":"Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy","volume":"17","author":"Coffin","year":"2011","journal-title":"Liver Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5005\/jp-journals-10018-1147","article-title":"Hepatitis B Virus Reactivation under Treatment with Nilotinib","volume":"5","author":"Temel","year":"2015","journal-title":"Euroasian J. Hepato-Gastroenterol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:36Z","timestamp":1760028576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["v17030388"],"URL":"https:\/\/doi.org\/10.3390\/v17030388","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]}}}